Management of Hypertension in Patients with Coronary Artery Disease

Initial Therapy and Blood Pressure Targets

• The American Heart Association recommends a target blood pressure of <140/90 mmHg for most patients, but <130/80 mmHg may be considered in selected high-risk patients with coronary artery disease 1
• The American College of Cardiology recommends a target blood pressure of <140/90 mmHg for the general population, and <130/80 mmHg for patients with cardiovascular disease, diabetes, or chronic kidney disease 2, 3
• Target BP may be lower (110-130 mmHg systolic) in certain cases, as recommended by the American Heart Association 4

Pharmacological Therapy

• Beta-blockers are recommended for patients with angina or post-myocardial infarction, and can be used in combination with other therapies such as ACE inhibitors, ARBs, and thiazide diuretics 1, 4
• Amlodipine can be used as first-line therapy in patients with coronary artery disease, especially if beta-blockers are contraindicated, and can be safely used in patients with heart failure with reduced ejection fraction 1
• Amlodipine 10 mg produces statistically significant reductions in both systolic and diastolic blood pressure, averaging about 12-13/6-7 mmHg, recognized by the European Society of Cardiology/European Society of Hypertension 5
• Recommended dosages for hypertension management include amlodipine 2.5-10 mg once daily 6
• Effective combinations include thiazide diuretic + ARB, thiazide diuretic + ACE inhibitor, and dihydropyridine CCB + ARB or ACE inhibitor, according to the American Heart Association 3
• Low-dose combination therapy with lower doses of multiple agents is recommended rather than maximum doses of a single agent, if blood pressure control remains inadequate 7

Special Considerations

• When initiating therapy for hypertension with coronary artery disease, blood pressure should be lowered gradually, especially in patients with elevated diastolic blood pressure and evidence of myocardial ischemia 1
• In older hypertensive individuals with wide pulse pressures, monitoring for very low diastolic blood pressure values (<60 mmHg) is recommended to avoid compromising coronary perfusion 1
• Amlodipine may cause dose-related pedal edema, more common in women than men, and may be used with caution in heart failure with reduced ejection fraction 6
• Patients experiencing peripheral edema with amlodipine may benefit from switching to lercanidipine or alternative therapies such as ACE inhibitors or ARBs, especially in elderly patients 1, 8, 9, 10

Contraindications and Precautions

• Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) should be avoided in patients with heart failure with reduced ejection fraction 1
• The American College of Cardiology recommends avoiding non-dihydropyridine calcium channel blockers (verapamil, diltiazem) in patients with heart failure with reduced ejection fraction 1, 8
• Adding spironolactone 25mg daily may be effective in resistant hypertension, but requires adequate kidney function (eGFR >45 mL/min) and normal potassium levels (<4.5 mEq/L) 9, 10

Medication Dosages and Indications

Monitoring and Follow-up

• The American College of Cardiology recommends checking blood pressure within 2-4 weeks after starting medication, and monitoring electrolytes (potassium, sodium) within 4 weeks of starting thiazide diuretics 2
• If target BP is not achieved, the American Heart Association recommends increasing the dose or adding a second agent, such as a long-acting calcium channel blocker or an ACE inhibitor 1
• Blood pressure should be checked within 2-4 weeks after medication change, and electrolyte abnormalities, particularly hyponatremia and hypokalemia, should be monitored, especially in the first few weeks 7, 4, 6, 9, 10